- Home
- MPW vs RDY Comparison
MPW vs RDY Comparison
Compare MPW & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPW
- RDY
- Stock Information
- Founded
- MPW 2003
- RDY 1984
- Country
- MPW United States
- RDY India
- Employees
- MPW N/A
- RDY N/A
- Industry
- MPW Real Estate Investment Trusts
- RDY Biotechnology: Pharmaceutical Preparations
- Sector
- MPW Real Estate
- RDY Health Care
- Exchange
- MPW Nasdaq
- RDY Nasdaq
- Market Cap
- MPW 2.4B
- RDY 2.5B
- IPO Year
- MPW 2005
- RDY N/A
- Fundamental
- Price
- MPW $4.33
- RDY $14.81
- Analyst Decision
- MPW Hold
- RDY Buy
- Analyst Count
- MPW 6
- RDY 1
- Target Price
- MPW $4.92
- RDY $17.00
- AVG Volume (30 Days)
- MPW 13.8M
- RDY 1.9M
- Earning Date
- MPW 02-19-2025
- RDY 01-23-2025
- Dividend Yield
- MPW 7.44%
- RDY 3.89%
- EPS Growth
- MPW N/A
- RDY 4.63
- EPS
- MPW N/A
- RDY 0.76
- Revenue
- MPW $660,172,000.00
- RDY $3,579,112,656.00
- Revenue This Year
- MPW N/A
- RDY $16.39
- Revenue Next Year
- MPW N/A
- RDY $8.74
- P/E Ratio
- MPW N/A
- RDY $19.50
- Revenue Growth
- MPW N/A
- RDY 12.37
- 52 Week Low
- MPW $3.08
- RDY $13.52
- 52 Week High
- MPW $6.55
- RDY $16.89
- Technical
- Relative Strength Index (RSI)
- MPW 61.22
- RDY 42.14
- Support Level
- MPW $3.93
- RDY $14.74
- Resistance Level
- MPW $4.23
- RDY $14.94
- Average True Range (ATR)
- MPW 0.23
- RDY 0.20
- MACD
- MPW 0.06
- RDY -0.12
- Stochastic Oscillator
- MPW 91.11
- RDY 7.32
About MPW Medical Properties Trust Inc. common stock
Medical Properties Trust Inc is a healthcare facility REIT. The company operates one segment, which owns and leases healthcare facilities. The vast majority of Medical's revenue is generated in the United States, followed by Germany and the United Kingdom. It provides financing for a variety of facilities that require funds for acquisitions, sale-leasebacks, new developments, and expansion projects.
About RDY Dr. Reddy's Laboratories Ltd
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.